<DOC>
	<DOCNO>NCT00416442</DOCNO>
	<brief_summary>This study design evaluate safety , tolerability pharmacokinetics single multiple-dose escalation RSV604 administer intravenously healthy subject .</brief_summary>
	<brief_title>Safety , Tolerability Pharmacokinetic Study Single Multiple Intravenous Doses RSV604 Healthy Subjects .</brief_title>
	<detailed_description />
	<criteria>Healthy male female subject , 1850 year age , good health determine past medical history , physical examination , vital sign , electrocardiogram , laboratory test screen . Vital sign within follow parameter : oral body temperature 35.037.5 Â°C systolic blood pressure , 85140 mm Hg diastolic blood pressure , 5090 mm Hg pulse rate , 40 100 beat per minute ( bpm ) Female subject must surgically sterilize least 6 month prior screen , supportive clinical documentation OR Postmenopausal woman must regular menstrual bleeding least 1 year prior inclusion . Body mass index ( BMI ) must within range 18 30 kg/m2 . Subjects must weigh least 50 kg participate study . Smokers ( use tobacco product previous 3 month ) . Smokers define subject report tobacco use urine cotinine great 300 ng/ml Participation clinical investigation involve medical intervention within 4 week study start Donation loss 400 ml blood within 8 week prior study start Significant illness within 2 week study start A past personal close family medical history clinically significant ECG abnormality prolong QTinterval syndrome . History autonomic dysfunction ( e.g . history fainting , orthostatic hypotension ) . History acute chronic bronchospastic disease ( include asthma chronic obstructive pulmonary disease , treat treat ) , History clinically significant drug allergy history atopic allergy ( asthma , urticaria , eczematous dermatitis ) . A known hypersensitivity study drug drug similar study drug particularly benzodiazepine . Any surgical medical condition might significantly alter absorption , distribution , metabolism excretion drug may jeopardize subject case participation study , include bowel , gastrointestinal , renal , pancreatic , hepatic , hematological , immunological , neurological disorder . Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>November 2011</verification_date>
	<keyword>healthy subject , safety , tolerability , dose escalation , pharmacokinetics , benzodiazepine</keyword>
	<keyword>Healthy male female subject</keyword>
</DOC>